newsfilter
← Latest News
GlobeNewswire·

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

  • Chemomab Therapeutics and Scipher Medicine have entered a definitive merger agreement to combine via a stock transaction, with the new entity operating as Scipher Medicine Corporation under the Nasdaq ticker "SCIP".
  • The combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, into a precision medicine Phase 2 trial for rheumatoid arthritis (RA) using Scipher's AI Network Medicine platform to identify therapeutic targets & select responsive patients.
  • Scipher's AI platform identified CCL24 as a top-ranked therapeutic target for RA & developed a proprietary response signature to support patient selection for nebokitug treatment.
  • A top-line readout for the RA Phase 2 trial is expected in the first half of 2028, serving as a key inflection point for the company.
  • A syndicate of investors led by Northpond Ventures committed to a $30 million private placement, bringing the combined company's valuation to $150 million before financing & providing a cash runway into the second half of 2028.
  • Dr. Reginald Seeto will serve as CEO of the combined company, while Chemomab co-founder Adi Mor, PhD, will join the Board of Directors.
  • Upon closing, pre-Merger Chemomab shareholders are expected to own approximately 32% of the combined company, pre-Merger Scipher shareholders approximately 68%, & Chemomab shareholders will receive contingent value rights (CVRs) tied to nebokitug milestones.
  • The transaction is expected to close in the fourth quarter of 2026, subject to shareholder approval, SEC registration statement effectiveness, & redomiciling of Chemomab to the United States.
  • Nebokitug targets CCL24 to address both inflammation & fibrosis, showing favorable safety & biomarker improvements in prior trials including the Phase 2 SPRING study for primary sclerosing cholangitis.
  • Scipher's portfolio includes revenue-generating businesses such as biopharma partnerships, an immunology data business, & the commercial precision medicine business featuring PrismRA®, the only CMS-approved test for predicting RA treatment response.
  • A joint conference call to discuss the merger is scheduled for July 8, 2026, at 8:30 AM ET.